SCHEMBL4037154

SCHEMBL4037154

COc1ccc2nc(-c3n[nH]c4ncc(Br)cc34)[nH]c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 2/20 0.51
FGFR1 P11362 2/20 0.50
CHEK1 O14757 1/20 0.49
NPC1 O15118 4/20 0.48
RAB9A P51151 3/20 0.48
TP53 P04637 3/20 0.48
HPGD P15428 3/20 0.48
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TSHR P16473 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
HSD17B10 Q99714 1/20 0.48
FLT3 P36888 3/20 0.48
CLK4 Q9HAZ1 1/20 0.47
RUNX1 Q01196 2/20 0.47
MEN1 O00255 2/20 0.46
POLB P06746 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4038471 0.81 RET (0.52) PDPK1FGFR1CHEK1NPC1RAB9A
SCHEMBL4043185 0.81 PDPK1 (0.67) PDPK1FGFR1CHEK1NPC1RAB9A
SCHEMBL28562998 0.78 DYRK1B (0.61) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL4033776 0.78 RET (0.74) PDPK1FGFR1CHEK1NPC1RAB9A
SCHEMBL4035396 0.78 PDPK1 (0.45) PDPK1FGFR1FLT3CLK4RUNX1
SCHEMBL3538044 0.76 ITK (0.67) PDPK1FGFR1CHEK1NPC1RAB9A
SCHEMBL29930535 0.75 GAA (0.49) SMN1; SMN2CLK4
SCHEMBL4039633 0.74 FGFR1 (0.41) PDPK1FGFR1CHEK1FLT3CLK4
SCHEMBL4036025 0.73 RET (0.70) PDPK1FGFR1RETERBB2CDK1
SCHEMBL4034227 0.73 RET (0.51) PDPK1FGFR1RETCBFBERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541367-B2 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-06-02 US disclosed
US-20090048249-A1 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-02-19 US disclosed
WO-2006130673-A1 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048249-A1 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders PRKDC, PRKACA, ABL1 PDPK1 90/4885FGFR1 508/4885CHEK1 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.